Posted by Michael Wonder on 11 May 2021
Expensive migraine drug Emgality added to PBS
11 May 2021 - An expensive migraine drug will be listed on the Pharmaceuticals Benefits Scheme, making it affordable for thousands of sufferers.
Migraine is the most common brain disease in the world, and 71% of sufferers are women. The condition costs the economy more than $3.5 billion a year.
Emgality (galcanezumab) will be listed on the PBS from 1 June, so instead of costing $6800 a year it will now cost $41.30 a script or $6.60 for concession card holders.
